Passive immunization against dental caries and periodontal disease: development of recombinant and human monoclonal antibodies.
Indigenous micro-organisms in the oral cavity can cause two major diseases, dental caries and periodontal diseases. There is neither agreement nor consensus as to the actual mechanisms of pathogenesis of the specific virulence factors of these micro-organisms. The complexity of the bacterial community in dental plaque has made it difficult for the single bacterial agent of dental caries to be determined. However, there is considerable evidence that Streptococcus mutans is implicated as the primary causative organism of dental caries, and the cell-surface protein antigen (SA I/II) as well as glucosyltransferases (GTFs) produced by S. mutans appear to be major colonization factors. Various forms of periodontal diseases are closely associated with specific subgingival bacteria. Porphyromonas gingivalis has been implicated as an important etiological agent of adult periodontitis. Adherence of bacteria to host tissues is a prerequisite for colonization and one of the important steps in the disease process. Bacterial coaggregation factors and hemagglutinins likely play major roles in colonization in the subgingival area. Emerging evidence suggests that inhibition of these virulence factors may protect the host against caries and periodontal disease. Active and passive immunization approaches have been developed for immunotherapy of these diseases. Recent advances in mucosal immunology and the introduction of novel strategies for inducing mucosal immune responses now raise the possibility that effective and safe vaccines can be constructed. In this regard, some successful results have been reported in animal experimental models. Nevertheless, since the public at large might be skeptical about the seriousness of oral diseases, immunotherapy must be carried out with absolute safety. For this goal to be achieved, the development of safe antibodies for passive immunization is significant and important. In this review, salient advances in passive immunization against caries and periodontal diseases are summarized, and the biotechnological approaches for developing recombinant and human-type antibodies are introduced. Furthermore, our own attempts to construct single-chain variable fragments (ScFv) and human-type antibodies capable of neutralizing virulence factors are discussed.
Abiko
Y
Y
Department of Biochemistry, Nihon University School of Dentistry at Matsudo, Chiba, Japan. yabiko@mascat.nihon-u.ac.jp
D018829:Adhesins, Bacterial / Q000276:immunology; D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000276:immunology; D001422:Bacterial Adhesion; D001426:Bacterial Proteins / Q000276:immunology; D001428:Bacterial Vaccines; D003731:Dental Caries / Q000382:microbiology / Q000517:prevention & control*; D004195:Disease Models, Animal; D000939:Epitopes / Q000276:immunology; D016695:Glycosyltransferases / Q000276:immunology; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology; D007116:Immunization, Passive; D007128:Immunoglobulin Fragments / Q000627:therapeutic use; D007135:Immunoglobulin Variable Region / Q000627:therapeutic use; D008562:Membrane Glycoproteins; D010510:Periodontal Diseases / Q000382:microbiology / Q000517:prevention & control*; D016966:Porphyromonas gingivalis / Q000276:immunology; D011994:Recombinant Proteins; D013295:Streptococcus mutans / Q000201:enzymology / Q000276:immunology; D014774:Virulence
D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D000939:Epitopes; D006388:Hemagglutinins; D007128:Immunoglobulin Fragments; D007135:Immunoglobulin Variable Region; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; C055764:S-layer proteins; D016695:Glycosyltransferases